View Financial HealthNirman Agri Genetics 배당 및 자사주 매입배당 기준 점검 3/6Nirman Agri Genetics 수익으로 충분히 충당되는 현재 수익률 3.96% 보유한 배당금 지급 회사입니다.핵심 정보4.0%배당 수익률0.0001%자사주 매입 수익률총 주주 수익률4.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향6%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • Apr 02Now 21% overvaluedOver the last 90 days, the stock has fallen 31% to ₹42.60. The fair value is estimated to be ₹35.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last year. Earnings per share has grown by 38%.Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹71.05, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 91x in the Biotechs industry in India. Total loss to shareholders of 82% over the past year.분석 기사 • Nov 28We Don’t Think Nirman Agri Genetics' (NSE:NIRMAN) Earnings Should Make Shareholders Too ComfortableInvestors appear disappointed with Nirman Agri Genetics Limited's ( NSE:NIRMAN ) recent earnings, despite the decent...Reported Earnings • Nov 20First half 2026 earnings released: EPS: ₹18.20 (vs ₹16.46 in 1H 2025)First half 2026 results: EPS: ₹18.20 (up from ₹16.46 in 1H 2025). Revenue: ₹1.46b (up 30% from 1H 2025). Net income: ₹145.8m (up 27% from 1H 2025). Profit margin: 10.0% (in line with 1H 2025).공시 • Nov 14Nirman Agri Genetics Limited to Report First Half, 2026 Results on Nov 14, 2025Nirman Agri Genetics Limited announced that they will report first half, 2026 results on Nov 14, 2025Valuation Update With 7 Day Price Move • Nov 03Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹95.05, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 104x in the Biotechs industry in India. Total loss to shareholders of 72% over the past year.New Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹843.4m (US$9.56m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). High level of non-cash earnings (97% accrual ratio). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Market cap is less than US$10m (₹843.4m market cap, or US$9.56m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (11% net profit margin).Board Change • Oct 11High number of new directorsNon-Executive Director Sagar Chavan was the last director to join the board, commencing their role in 2025.분석 기사 • Oct 09A Piece Of The Puzzle Missing From Nirman Agri Genetics Limited's (NSE:NIRMAN) 31% Share Price ClimbNirman Agri Genetics Limited ( NSE:NIRMAN ) shareholders are no doubt pleased to see that the share price has bounced...Valuation Update With 7 Day Price Move • Oct 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹170, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 61x in the Biotechs industry in India. Total loss to shareholders of 50% over the past year.New Risk • Sep 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.2% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.12b market cap, or US$12.6m).Buy Or Sell Opportunity • Sep 18Now 20% overvaluedOver the last 90 days, the stock has fallen 1.5% to ₹200. The fair value is estimated to be ₹166, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹164, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 63x in the Biotechs industry in India. Total loss to shareholders of 61% over the past year.공시 • Sep 10Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2025Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2025, at 13:00 Indian Standard Time.New Risk • Aug 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹872.7m market cap, or US$10.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin).New Risk • Aug 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹873.9m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹873.9m market cap, or US$9.97m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin).Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹148, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 55x in the Biotechs industry in India. Total loss to shareholders of 60% over the past year.New Risk • Jul 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.05b market cap, or US$12.2m).분석 기사 • Jul 19Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price SlumpUnfortunately for some shareholders, the Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has dived 26% in the...분석 기사 • Jul 19Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price SlumpUnfortunately for some shareholders, the Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has dived 26% in the...Buy Or Sell Opportunity • Jun 23Now 21% overvaluedOver the last 90 days, the stock has fallen 7.7% to ₹205. The fair value is estimated to be ₹169, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₹204, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 9.9% over the past year.Board Change • May 14High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹260, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 48x in the Biotechs industry in India. Total returns to shareholders of 35% over the past year.New Risk • Apr 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.7% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.36b market cap, or US$15.9m).분석 기사 • Mar 29Investors Give Nirman Agri Genetics Limited (NSE:NIRMAN) Shares A 27% HidingTo the annoyance of some shareholders, Nirman Agri Genetics Limited ( NSE:NIRMAN ) shares are down a considerable 27...Valuation Update With 7 Day Price Move • Mar 25Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹222, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 52x in the Biotechs industry in India. Total returns to shareholders of 28% over the past year.Buy Or Sell Opportunity • Mar 24Now 21% overvaluedOver the last 90 days, the stock has fallen 46% to ₹211. The fair value is estimated to be ₹175, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.분석 기사 • Mar 19Calculating The Intrinsic Value Of Nirman Agri Genetics Limited (NSE:NIRMAN)Key Insights Using the 2 Stage Free Cash Flow to Equity, Nirman Agri Genetics fair value estimate is ₹175 Current share...Valuation Update With 7 Day Price Move • Mar 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹227, the stock trades at a trailing P/E ratio of 6.3x. Average trailing P/E is 47x in the Biotechs industry in India. Total returns to shareholders of 11% over the past year.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to ₹263, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 54x in the Biotechs industry in India. Total returns to shareholders of 1.2% over the past year.분석 기사 • Feb 12Nirman Agri Genetics Limited (NSE:NIRMAN) Stock's 28% Dive Might Signal An Opportunity But It Requires Some ScrutinyNirman Agri Genetics Limited ( NSE:NIRMAN ) shares have had a horrible month, losing 28% after a relatively good period...New Risk • Feb 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.72b market cap, or US$19.8m).New Risk • Feb 06New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹2.13b market cap, or US$24.3m).Reported Earnings • Feb 06Third quarter 2025 earnings released: EPS: ₹8.40 (vs ₹5.60 in 3Q 2024)Third quarter 2025 results: EPS: ₹8.40 (up from ₹5.60 in 3Q 2024). Revenue: ₹610.7m (up 199% from 3Q 2024). Net income: ₹67.3m (up 101% from 3Q 2024). Profit margin: 11% (down from 16% in 3Q 2024). The decrease in margin was driven by higher expenses.공시 • Jan 09+ 1 more updateNirman Agri Genetics Limited Announces the Resignation of Sandipan Baburao Bhawar as Chief Financial OfficerNirman Agri Genetics Limited informed that Mr. Sandipan Baburao Bhawar has tendered his resignation from the Post of Chief Financial Officer (CFO) and KMP of the Company effective from January 8, 2025 (after the closing of business hours) on account of reasons as mentioned in resignation letter attached herewith. The Company is in the process of appointing a new Chief Financial Officer and the same will be communicated to the Stock Exchange in due course.분석 기사 • Jan 08Should You Be Adding Nirman Agri Genetics (NSE:NIRMAN) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Board Change • Jan 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 19High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 15Second quarter 2025 earnings released: EPS: ₹8.01 (vs ₹5.60 in 2Q 2024)Second quarter 2025 results: EPS: ₹8.01 (up from ₹5.60 in 2Q 2024). Revenue: ₹620.9m (up 204% from 2Q 2024). Net income: ₹64.2m (up 92% from 2Q 2024). Profit margin: 10% (down from 16% in 2Q 2024). The decrease in margin was driven by higher expenses.공시 • Sep 27Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2024Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2024, at 12:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Sep 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹346, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 99% over the past year.Reported Earnings • Aug 15First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: ₹8.45. Net income: ₹50.4m (up ₹50.4m from 1Q 2024).Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹439, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 29x in the Biotechs industry in India. Total returns to shareholders of 219% over the past year.분석 기사 • Aug 13Here's Why We Think Nirman Agri Genetics (NSE:NIRMAN) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹439, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 124% over the past year.분석 기사 • Jul 03Nirman Agri Genetics Limited (NSE:NIRMAN) Stock Rockets 47% But Many Are Still Ignoring The CompanyThe Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has done very well over the last month, posting an...Valuation Update With 7 Day Price Move • Jul 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹249, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 87% over the past year.New Risk • Jun 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risk Market cap is less than US$100m (₹1.10b market cap, or US$13.2m).Valuation Update With 7 Day Price Move • Jun 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹185, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 70% over the past year.공시 • Jun 01Nirman Agri Genetics Limited to Report Second Half, 2024 Results on May 30, 2024Nirman Agri Genetics Limited announced that they will report second half, 2024 results on May 30, 2024Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹17.46 (vs ₹6.72 in FY 2023)Full year 2024 results: EPS: ₹17.46 (up from ₹6.72 in FY 2023). Revenue: ₹633.4m (up 121% from FY 2023). Net income: ₹104.0m (up 160% from FY 2023). Profit margin: 16% (up from 14% in FY 2023). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹223, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 35x in the Biotechs industry in India. Total returns to shareholders of 204% over the past year.공시 • Apr 19Nirman Agri Genetics Limited Receives License from Department of Agriculture, Government of TelanganaNirman Agri Genetics Limited informed to the Stakeholders that the Company has been granted with License from the Government of Telangana to carry on the business of a dealer in seeds for various purposes in the State of Telangana. It will help in expanding and tapping new geographical markets. This license will magnificently support to increase revenues. Name of the regulatory or licensing authority: Department of Agriculture, Government of Telangana. Brief details of the approval/license: The Company has been granted license to sell, export, import and store the Agriculture Seeds for the various purposes in the State of Telangana. Access to this License will help in dealing of Paddy seeds in the State of Telangana. Period for which such license is valid: 5 years (From February 26, 2024 to February 24, 2029).Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹178, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 32x in the Biotechs industry in India. Total returns to shareholders of 85% over the past year.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹190, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 33x in the Biotechs industry in India.Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹258, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 53x in the Biotechs industry in India.Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹214, the stock trades at a trailing P/E ratio of 31.8x. Average trailing P/E is 32x in the Biotechs industry in India.공시 • Sep 13Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2023Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2023, at 12:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2023 and the Reports of the Board of Directors and Auditors thereon; to Re-appoint Mr. Avinash Bhimrao Bagal, Non-Executive Non-Independent Director, who retires by rotation and being eligible, offers himself for re-appointment; to Approve the Appointment of M/s. Devendra C Belan & Associates, Chartered Accountants (ICAI Firm Registration Number: 126495W) as the Statutory Auditor of the Company for a period of 5 years; i.e. from the conclusion of this Annual General Meeting till the conclusion of Next Annual General Meeting from this Annual General Meeting; and to discuss other matters.Valuation Update With 7 Day Price Move • Aug 24Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹178, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 35x in the Biotechs industry in India.New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹815.4m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). High level of non-cash earnings (28% accrual ratio). Market cap is less than US$10m (₹815.4m market cap, or US$9.85m). Minor Risk Revenue is less than US$5m (₹286m revenue, or US$3.5m).Valuation Update With 7 Day Price Move • Aug 07Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹161, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 37x in the Biotechs industry in Asia.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹147, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 38x in the Biotechs industry in Asia.Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹96.90, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 39x in the Biotechs industry in Asia.Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 26%After last week's 26% share price gain to ₹76.75, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 17x in the Biotechs industry in India.Valuation Update With 7 Day Price Move • Apr 12Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹67.70, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 17x in the Biotechs industry in India.Board Change • Mar 31High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, NIRMAN 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: NIRMAN 2 년 동안만 배당금을 지급해 왔으며 그 이후로 지급액이 증가하지 않았습니다.배당 수익률 vs 시장Nirman Agri Genetics 배당 수익률 vs 시장NIRMAN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NIRMAN)4.0%시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (Biotechs)1.3%분석가 예측 (NIRMAN) (최대 3년)n/a주목할만한 배당금: NIRMAN 의 배당금( 3.96% )은 Indian 시장에서 배당금 지급자의 하위 25%( 0.3% )보다 높습니다.고배당: NIRMAN 의 배당금( 3.96% )은 Indian 시장( 1.48% )주주 대상 이익 배당수익 보장: 낮은 배당금 지급 비율 (5.6%)로 인해 NIRMAN의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: NIRMAN 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 20:38종가2026/05/22 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nirman Agri Genetics Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Buy Or Sell Opportunity • Apr 02Now 21% overvaluedOver the last 90 days, the stock has fallen 31% to ₹42.60. The fair value is estimated to be ₹35.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last year. Earnings per share has grown by 38%.
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹71.05, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 91x in the Biotechs industry in India. Total loss to shareholders of 82% over the past year.
분석 기사 • Nov 28We Don’t Think Nirman Agri Genetics' (NSE:NIRMAN) Earnings Should Make Shareholders Too ComfortableInvestors appear disappointed with Nirman Agri Genetics Limited's ( NSE:NIRMAN ) recent earnings, despite the decent...
Reported Earnings • Nov 20First half 2026 earnings released: EPS: ₹18.20 (vs ₹16.46 in 1H 2025)First half 2026 results: EPS: ₹18.20 (up from ₹16.46 in 1H 2025). Revenue: ₹1.46b (up 30% from 1H 2025). Net income: ₹145.8m (up 27% from 1H 2025). Profit margin: 10.0% (in line with 1H 2025).
공시 • Nov 14Nirman Agri Genetics Limited to Report First Half, 2026 Results on Nov 14, 2025Nirman Agri Genetics Limited announced that they will report first half, 2026 results on Nov 14, 2025
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹95.05, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 104x in the Biotechs industry in India. Total loss to shareholders of 72% over the past year.
New Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹843.4m (US$9.56m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). High level of non-cash earnings (97% accrual ratio). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Market cap is less than US$10m (₹843.4m market cap, or US$9.56m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (11% net profit margin).
Board Change • Oct 11High number of new directorsNon-Executive Director Sagar Chavan was the last director to join the board, commencing their role in 2025.
분석 기사 • Oct 09A Piece Of The Puzzle Missing From Nirman Agri Genetics Limited's (NSE:NIRMAN) 31% Share Price ClimbNirman Agri Genetics Limited ( NSE:NIRMAN ) shareholders are no doubt pleased to see that the share price has bounced...
Valuation Update With 7 Day Price Move • Oct 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹170, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 61x in the Biotechs industry in India. Total loss to shareholders of 50% over the past year.
New Risk • Sep 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.2% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.12b market cap, or US$12.6m).
Buy Or Sell Opportunity • Sep 18Now 20% overvaluedOver the last 90 days, the stock has fallen 1.5% to ₹200. The fair value is estimated to be ₹166, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹164, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 63x in the Biotechs industry in India. Total loss to shareholders of 61% over the past year.
공시 • Sep 10Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2025Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2025, at 13:00 Indian Standard Time.
New Risk • Aug 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹872.7m market cap, or US$10.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin).
New Risk • Aug 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹873.9m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹873.9m market cap, or US$9.97m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin).
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹148, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 55x in the Biotechs industry in India. Total loss to shareholders of 60% over the past year.
New Risk • Jul 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.05b market cap, or US$12.2m).
분석 기사 • Jul 19Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price SlumpUnfortunately for some shareholders, the Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has dived 26% in the...
분석 기사 • Jul 19Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price SlumpUnfortunately for some shareholders, the Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has dived 26% in the...
Buy Or Sell Opportunity • Jun 23Now 21% overvaluedOver the last 90 days, the stock has fallen 7.7% to ₹205. The fair value is estimated to be ₹169, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.
Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₹204, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 9.9% over the past year.
Board Change • May 14High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹260, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 48x in the Biotechs industry in India. Total returns to shareholders of 35% over the past year.
New Risk • Apr 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.7% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.36b market cap, or US$15.9m).
분석 기사 • Mar 29Investors Give Nirman Agri Genetics Limited (NSE:NIRMAN) Shares A 27% HidingTo the annoyance of some shareholders, Nirman Agri Genetics Limited ( NSE:NIRMAN ) shares are down a considerable 27...
Valuation Update With 7 Day Price Move • Mar 25Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹222, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 52x in the Biotechs industry in India. Total returns to shareholders of 28% over the past year.
Buy Or Sell Opportunity • Mar 24Now 21% overvaluedOver the last 90 days, the stock has fallen 46% to ₹211. The fair value is estimated to be ₹175, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.
분석 기사 • Mar 19Calculating The Intrinsic Value Of Nirman Agri Genetics Limited (NSE:NIRMAN)Key Insights Using the 2 Stage Free Cash Flow to Equity, Nirman Agri Genetics fair value estimate is ₹175 Current share...
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹227, the stock trades at a trailing P/E ratio of 6.3x. Average trailing P/E is 47x in the Biotechs industry in India. Total returns to shareholders of 11% over the past year.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to ₹263, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 54x in the Biotechs industry in India. Total returns to shareholders of 1.2% over the past year.
분석 기사 • Feb 12Nirman Agri Genetics Limited (NSE:NIRMAN) Stock's 28% Dive Might Signal An Opportunity But It Requires Some ScrutinyNirman Agri Genetics Limited ( NSE:NIRMAN ) shares have had a horrible month, losing 28% after a relatively good period...
New Risk • Feb 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.72b market cap, or US$19.8m).
New Risk • Feb 06New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹2.13b market cap, or US$24.3m).
Reported Earnings • Feb 06Third quarter 2025 earnings released: EPS: ₹8.40 (vs ₹5.60 in 3Q 2024)Third quarter 2025 results: EPS: ₹8.40 (up from ₹5.60 in 3Q 2024). Revenue: ₹610.7m (up 199% from 3Q 2024). Net income: ₹67.3m (up 101% from 3Q 2024). Profit margin: 11% (down from 16% in 3Q 2024). The decrease in margin was driven by higher expenses.
공시 • Jan 09+ 1 more updateNirman Agri Genetics Limited Announces the Resignation of Sandipan Baburao Bhawar as Chief Financial OfficerNirman Agri Genetics Limited informed that Mr. Sandipan Baburao Bhawar has tendered his resignation from the Post of Chief Financial Officer (CFO) and KMP of the Company effective from January 8, 2025 (after the closing of business hours) on account of reasons as mentioned in resignation letter attached herewith. The Company is in the process of appointing a new Chief Financial Officer and the same will be communicated to the Stock Exchange in due course.
분석 기사 • Jan 08Should You Be Adding Nirman Agri Genetics (NSE:NIRMAN) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Board Change • Jan 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 19High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 15Second quarter 2025 earnings released: EPS: ₹8.01 (vs ₹5.60 in 2Q 2024)Second quarter 2025 results: EPS: ₹8.01 (up from ₹5.60 in 2Q 2024). Revenue: ₹620.9m (up 204% from 2Q 2024). Net income: ₹64.2m (up 92% from 2Q 2024). Profit margin: 10% (down from 16% in 2Q 2024). The decrease in margin was driven by higher expenses.
공시 • Sep 27Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2024Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2024, at 12:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Sep 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹346, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 99% over the past year.
Reported Earnings • Aug 15First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: ₹8.45. Net income: ₹50.4m (up ₹50.4m from 1Q 2024).
Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹439, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 29x in the Biotechs industry in India. Total returns to shareholders of 219% over the past year.
분석 기사 • Aug 13Here's Why We Think Nirman Agri Genetics (NSE:NIRMAN) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹439, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 124% over the past year.
분석 기사 • Jul 03Nirman Agri Genetics Limited (NSE:NIRMAN) Stock Rockets 47% But Many Are Still Ignoring The CompanyThe Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has done very well over the last month, posting an...
Valuation Update With 7 Day Price Move • Jul 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹249, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 87% over the past year.
New Risk • Jun 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risk Market cap is less than US$100m (₹1.10b market cap, or US$13.2m).
Valuation Update With 7 Day Price Move • Jun 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹185, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 70% over the past year.
공시 • Jun 01Nirman Agri Genetics Limited to Report Second Half, 2024 Results on May 30, 2024Nirman Agri Genetics Limited announced that they will report second half, 2024 results on May 30, 2024
Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹17.46 (vs ₹6.72 in FY 2023)Full year 2024 results: EPS: ₹17.46 (up from ₹6.72 in FY 2023). Revenue: ₹633.4m (up 121% from FY 2023). Net income: ₹104.0m (up 160% from FY 2023). Profit margin: 16% (up from 14% in FY 2023). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹223, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 35x in the Biotechs industry in India. Total returns to shareholders of 204% over the past year.
공시 • Apr 19Nirman Agri Genetics Limited Receives License from Department of Agriculture, Government of TelanganaNirman Agri Genetics Limited informed to the Stakeholders that the Company has been granted with License from the Government of Telangana to carry on the business of a dealer in seeds for various purposes in the State of Telangana. It will help in expanding and tapping new geographical markets. This license will magnificently support to increase revenues. Name of the regulatory or licensing authority: Department of Agriculture, Government of Telangana. Brief details of the approval/license: The Company has been granted license to sell, export, import and store the Agriculture Seeds for the various purposes in the State of Telangana. Access to this License will help in dealing of Paddy seeds in the State of Telangana. Period for which such license is valid: 5 years (From February 26, 2024 to February 24, 2029).
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹178, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 32x in the Biotechs industry in India. Total returns to shareholders of 85% over the past year.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹190, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 33x in the Biotechs industry in India.
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹258, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 53x in the Biotechs industry in India.
Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹214, the stock trades at a trailing P/E ratio of 31.8x. Average trailing P/E is 32x in the Biotechs industry in India.
공시 • Sep 13Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2023Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2023, at 12:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2023 and the Reports of the Board of Directors and Auditors thereon; to Re-appoint Mr. Avinash Bhimrao Bagal, Non-Executive Non-Independent Director, who retires by rotation and being eligible, offers himself for re-appointment; to Approve the Appointment of M/s. Devendra C Belan & Associates, Chartered Accountants (ICAI Firm Registration Number: 126495W) as the Statutory Auditor of the Company for a period of 5 years; i.e. from the conclusion of this Annual General Meeting till the conclusion of Next Annual General Meeting from this Annual General Meeting; and to discuss other matters.
Valuation Update With 7 Day Price Move • Aug 24Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹178, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 35x in the Biotechs industry in India.
New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹815.4m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). High level of non-cash earnings (28% accrual ratio). Market cap is less than US$10m (₹815.4m market cap, or US$9.85m). Minor Risk Revenue is less than US$5m (₹286m revenue, or US$3.5m).
Valuation Update With 7 Day Price Move • Aug 07Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹161, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 37x in the Biotechs industry in Asia.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹147, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 38x in the Biotechs industry in Asia.
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹96.90, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 39x in the Biotechs industry in Asia.
Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 26%After last week's 26% share price gain to ₹76.75, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 17x in the Biotechs industry in India.
Valuation Update With 7 Day Price Move • Apr 12Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹67.70, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 17x in the Biotechs industry in India.
Board Change • Mar 31High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.